Insider Selling: Precision BioSciences (NASDAQ:DTIL) CEO Sells 20,559 Shares of Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 20,559 shares of Precision BioSciences stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $3.84, for a total value of $78,946.56. Following the completion of the sale, the chief executive officer owned 243,392 shares of the company’s stock, valued at $934,625.28. This trade represents a 7.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Amoroso also recently made the following trade(s):

• On Thursday, January 22nd, Michael Amoroso sold 34,799 shares of Precision BioSciences stock. The stock was sold at an average price of $4.17, for a total transaction of $145,111.83.

Precision BioSciences Trading Up 1.8%

Shares of DTIL traded up $0.07 during mid-day trading on Thursday, hitting $3.92. The company had a trading volume of 214,558 shares, compared to its average volume of 225,532. The stock has a market cap of $89.77 million, a PE ratio of -0.47 and a beta of 1.31. The business’s 50-day simple moving average is $4.16 and its 200-day simple moving average is $5.01. Precision BioSciences, Inc. has a 1-year low of $3.53 and a 1-year high of $8.82. The company has a quick ratio of 3.45, a current ratio of 3.45 and a debt-to-equity ratio of 1.35.

Hedge Funds Weigh In On Precision BioSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. HBK Sorce Advisory LLC purchased a new stake in shares of Precision BioSciences during the fourth quarter valued at approximately $38,000. Engineers Gate Manager LP acquired a new stake in Precision BioSciences during the 4th quarter valued at $43,000. Occudo Quantitative Strategies LP acquired a new stake in Precision BioSciences during the 4th quarter valued at $52,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Precision BioSciences during the 3rd quarter worth $72,000. Finally, Miller Financial Services LLC lifted its holdings in Precision BioSciences by 50.0% in the 4th quarter. Miller Financial Services LLC now owns 15,000 shares of the company’s stock worth $62,000 after buying an additional 5,000 shares in the last quarter. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $60.00.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.